SYNLAB AG

HM:SYAB Germany
Market Cap
$122.61K
€119.45K EUR
Market Cap Rank
#17262 Global
#1798 in Germany
Share Price
€12.93
Change (1 day)
-0.08%
52-Week Range
€11.36 - €12.99
All Time High
€22.16
About

SYNLAB AG provides medical diagnostic services and specialty testing services for hospitals, practicing doctors, clinics, patients, governments, and corporations primarily in Europe. SYNLAB AG was founded in 1998 and is based in Munich, Germany.

SYNLAB AG (SYAB) - Net Assets

Latest net assets as of March 2024: €2.37 Billion EUR

Based on the latest financial reports, SYNLAB AG (SYAB) has net assets worth €2.37 Billion EUR as of March 2024.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€4.71 Billion) and total liabilities (€2.34 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets €2.37 Billion
% of Total Assets 50.35%
Annual Growth Rate 24.8%
5-Year Change N/A
10-Year Change N/A
Growth Volatility 40.37

SYNLAB AG - Net Assets Trend (2020–2023)

This chart illustrates how SYNLAB AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for SYNLAB AG (2020–2023)

The table below shows the annual net assets of SYNLAB AG from 2020 to 2023.

Year Net Assets Change
2023-12-31 €2.34 Billion +0.21%
2022-12-31 €2.33 Billion +3.44%
2021-12-31 €2.26 Billion +87.42%
2020-12-31 €1.20 Billion --

Equity Component Analysis

This analysis shows how different components contribute to SYNLAB AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 35495500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2023)

Component Amount Percentage
Other Components €3.14 Billion 134.14%
Total Equity €2.34 Billion 100.00%

SYNLAB AG Competitors by Market Cap

The table below lists competitors of SYNLAB AG ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in SYNLAB AG's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2022 to 2023, total equity changed from 2,333,171,000 to 2,340,398,000, a change of 7,227,000 (0.3%).
  • Net income of 92,274,000 contributed positively to equity growth.
  • Dividend payments of 76,934,000 reduced retained earnings.
  • New share issuances of 203,000 increased equity.

Equity Change Factors (2022 to 2023)

Factor Impact Contribution
Net Income €92.27 Million +3.94%
Dividends Paid €76.93 Million -3.29%
Share Issuances €203.00K +0.01%
Other Changes €-8.32 Million -0.36%
Total Change €- 0.31%

Book Value vs Market Value Analysis

This analysis compares SYNLAB AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.21x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 2.38x to 1.21x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2020-12-31 €5.43 €12.93 x
2021-12-31 €10.16 €12.93 x
2022-12-31 €10.62 €12.93 x
2023-12-31 €10.65 €12.93 x

Capital Efficiency Dashboard

This dashboard shows how efficiently SYNLAB AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 3.94%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 3.50%
  • • Asset Turnover: 0.57x
  • • Equity Multiplier: 1.99x
  • Recent ROE (3.94%) is below the historical average (14.86%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2020 21.36% 9.83% 0.50x 4.38x €137.00 Million
2021 27.68% 16.59% 0.69x 2.40x €399.08 Million
2022 6.46% 4.64% 0.60x 2.31x €-82.62 Million
2023 3.94% 3.50% 0.57x 1.99x €-141.77 Million

Industry Comparison

This section compares SYNLAB AG's net assets metrics with peer companies in the same industry.

Industry Context

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
SYNLAB AG (SYAB) €2.37 Billion 21.36% 0.99x $125.49 Million
Hanna Capital Corp (04U1) $-79.29K 0.00% 0.00x $116.52K
WESTMINSTER RES (08W) $4.66 Million -31.33% 0.12x $5.16 Million
Axonics Inc (0I3) $570.14 Million -10.47% 0.16x $3.29 Billion
Global Bioenergies SA (1DK) $14.81 Million -86.04% 0.89x $369.68K
GIEAG Immobilien AG (2GI) $41.80 Million 40.21% 8.93x $15.57K
2invest AG (2INV) $82.61 Million -2.29% 0.06x $13.67 Million
PT Central Proteina Prima Tbk (4PT) $3.42 Trillion 11.74% 1.00x $6.90 Million
DGH Deutsche Grundwert Holding AG (5TR) $0.00 0.00% 0.00x $18.45K
SOFTCHOICE CORP. (90Q) $58.23 Million -19.76% 10.01x $470.36 Million
ALBA SE (ABA) $142.95 Million 5.25% 0.45x $5.10 Million